World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
47791
World Ranking
14349
National Ranking
548

Overview

Paul Baas is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands. Their research primarily focuses on medicine, with significant contributions to pulmonary and respiratory medicine and oncology. They have also worked in biotechnology, immunology, and radiology, nuclear medicine, and imaging.

The scientist's research covers a range of topics including:

  • Occupational and environmental lung diseases
  • Cancer immunotherapy and biomarkers
  • Pleural and pulmonary diseases
  • Lung cancer treatments and mutations
  • Interstitial lung diseases and idiopathic pulmonary fibrosis
  • Lung cancer diagnosis and treatment
  • Cancer research and treatments

Their body of work includes numerous scientific papers published in various journals, with a particular emphasis on lung cancer and immunotherapy. Key recent papers authored or co-authored by Paul Baas include:

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet
  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, 2020, The Lancet Respiratory Medicine
  • Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study, 2020, Journal of Clinical Oncology
  • First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743, 2022, Annals of Oncology

Frequent co-authors collaborating with Paul Baas include:

  • Joachim G.J.V. Aerts
  • Aaron S. Mansfield
  • Robin Cornelissen
  • Arnaud Scherpereel
  • Solange Peters

Paul Baas has contributed significantly to several publication venues, with the largest number of articles appearing in:

  • Journal of Thoracic Oncology
  • Lung Cancer
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Translational Lung Cancer Research

Their work is characterized by an emphasis on clinical trials and investigations into treatments for lung cancer and pleural diseases, particularly exploring immunotherapy approaches such as nivolumab, ipilimumab, and pembrolizumab. This research aligns with their broader interests across oncology and pulmonary medicine.

Best Publications

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • Photodynamic Therapy in Oncology

    Martijn Triesscheijn;Paul Baas;Jan H. M. Schellens;Jan H. M. Schellens;Fiona A. Stewart

  • Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

    Willemijn S. M. E. Theelen;Heike M. U. Peulen;Ferry Lalezari;Vincent van der Noort

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

    Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

    A Scherpereel;P Astoul;P Baas;T Berghmans

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

    Suzanne Leijen;Sjaak A. Burgers;Paul Baas;Dick Pluim

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. Baas;D. Fennell;K. M. Kerr;P. E. Van Schil

  • Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.

    Willemijn S.M.E. Theelen;Dawei Chen;Vivek Verma;Brian Paul Hobbs

  • Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

    Michele Carbone;Prasad S. Adusumilli;H. Richard Alexander;Paul Baas

  • Photodynamic therapy: a promising new modality for the treatment of cancer

    J.J. Schuitmaker;P. Baas;H.L.L.M. van Leengoed;F.W. van der Meulen

  • Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

    Keith M. Kerr;Lukas Bubendorf;Martin J. Edelman;Antonio Marchetti

  • A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

    George R Blumenschein;E. F. Smit;D. Planchard;D. W. Kim

  • Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

    Armando Santoro;Mary E. O'Brien;Rolf A. Stahel;Kristiaan Nackaerts

  • 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

    B. Besse;A. Adjei;P. Baas;P. Meldgaard

Frequent Co-Authors

Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Solange Peters
Solange Peters University Hospital of Lausanne
Roy S. Herbst
Roy S. Herbst Yale University
Jan H.M. Schellens
Jan H.M. Schellens Utrecht University
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Rolf A. Stahel
Rolf A. Stahel University of Zurich
Egbert F. Smit
Egbert F. Smit VU University Medical Center
Jos H. Beijnen
Jos H. Beijnen Utrecht University
Anna K. Nowak
Anna K. Nowak University of Western Australia
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require the traditional path. There are numerous 6 month lpn program online options for those seeking a fast-track entry into healthcare. Licensed Practical Nurse (LPN) programs are an excellent starting point, offering entry-level experience and the ability to begin working quickly.

For those interested in advanced practice roles, psych nurse practitioner programs provide the specialized training needed to work in psychiatric and mental health settings. These online programs are designed for registered nurses looking to expand their career options and make a difference in mental healthcare.

Healthcare administration is another in-demand field that supports the medical system from behind the scenes. If affordability is a key concern, consider the cheapest online healthcare administration degree programs. These degrees can be completed fully online and open doors in hospital management, policy, and beyond.

For those aiming for leadership roles, pursuing one of the cheapest mha programs online is an efficient way to enhance your qualifications. An online Master of Healthcare Administration (MHA) prepares graduates for high-level positions in healthcare organizations—without the burden of excessive tuition costs.

Best Scientists Citing Paul Baas

Trending Scientists

Recently Published Articles